Market Overview
The global separate biochemical analyzer market was valued at USD 1.8 billion in 2023 and is projected to reach USD 2.7 billion by 2030, growing at a CAGR of 6.2% during the forecast period. This growth is primarily driven by the increasing prevalence of chronic diseases requiring frequent monitoring, rising healthcare expenditure globally, and technological advancements in point-of-care testing devices.
Separate biochemical analyzers, also known as discrete analyzers, are automated clinical laboratory instruments that perform multiple biochemical tests on individual specimens sequentially rather than in batches. This allows for greater flexibility in test selection and faster turnaround times for individual samples compared to traditional batch analyzers. Key manufacturers in this space include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Danaher Corporation (Beckman Coulter), and Thermo Fisher Scientific, who collectively held over 55% of the market share in 2023.
Market size
USD 1.8 billion in 2023
2032
USD 2.7 billion by 2030
CAGR of 6.2% CAGR
Automatic Analyzers
Semi-Automatic Analyzers
Automatic Analyzers are gaining traction due to their ability to minimize human error and increase throughput, while Semi-Automatic Analyzers remain relevant in settings requiring human supervision for specialized testing protocols.
Clinical Diagnostics
Research Laboratories
Point-of-Care Testing
Veterinary Medicine
Clinical Diagnostics dominates due to the high volume of routine testing in hospitals and clinics, while Research Laboratories drive innovation through specialized analytical requirements and custom testing protocols.
https://www.24lifesciences.com
Our Key Players
Roche Diagnostics (Switzerland)
Siemens Healthineers (Germany)
Danaher Corporation (USA)
Abbott Laboratories (USA)
bioMérieux SA (France)
Ortho Clinical Diagnostics (USA)
Shenzhen Mindray Bio-Medical Electronics (China)
https://www.24lifesciences.com
